REFRACTORY COLORECTAL ADENOCARCINOMA
Clinical trials for REFRACTORY COLORECTAL ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY COLORECTAL ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for REFRACTORY COLORECTAL ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for tough colorectal cancer: experimental drug combo enters human testing
Disease control TerminatedThis early-phase trial is testing whether adding an experimental drug called ZEN003694 to two approved cancer drugs (cetuximab and encorafenib) can help patients with a specific type of advanced colorectal cancer that has not responded to prior treatments. The study involves 30 a…
Matched conditions: REFRACTORY COLORECTAL ADENOCARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for tough colorectal cancer: drug combo shows promise
Disease control OngoingThis study tests two drugs, panitumumab and trametinib, in people with stage IV colorectal cancer that no longer responds to standard treatments. The goal is to see if these drugs can shrink tumors or slow cancer growth. About 59 participants will receive either panitumumab alone…
Matched conditions: REFRACTORY COLORECTAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC